

February 25, 2025

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sir/Madam,

Sub: Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

In compliance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Davuluri Ownership Trust has acquired 32,53,890 equity shares of Neuland Laboratories Limited (i.e. 25.36 % stake) between February 24 & 25, 2025. The relevant disclosure under the aforementioned regulation is enclosed as **Annexure 1**.

The shares have been acquired pursuant to exemption Order of SEBI, dated January 03, 2025 issued under Regulation 11(5) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in the matter concerning proposed acquisition of shares and voting rights by Davuluri Ownership Trust.

This is for your information and records.

Thanking you,

Yours faithfully,
For Davuluri Ownership Trust

Sucheth Rao Davuluri
Trustee



Encl: As above

CC: **The Company Secretary, Neuland Laboratories Limited**
11th Floor (5th Level), Phoenix IVY Building,
Plot No. 573A-III, Road No. 82, Jubilee Hills,
Hyderabad, 500033, Telangana, India

Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A - Details of the Acquisition

Name of the Target Company (TC)	Neuland Laboratories Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Davuluri Ownership Trust		
Whether the acquirer belongs to Promoter / Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. The National Stock Exchange of India Ltd		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights			
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
Total (a+b+c+d)			
Details of acquisition			
a) Shares carrying voting rights acquired	32,53,890	25.36	25.36
b) VRs acquired otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
Total (a+b+c+d)	32,53,890	25.36	25.36



After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	32,53,890	25.36	25.36
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)			
Total (a+b+c+d)	32,53,890	25.36	25.36
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)	Inter-se acquired pursuant to exemption Order of SEBI, dated January 03, 2025 issued under Regulation 11(5) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in the matter concerning proposed acquisition of shares and voting rights by Davuluri Ownership Trust.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not Applicable		
Date of acquisition of / date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	24/02/2025 – 25/02/2025		
Equity share capital / total voting capital of the TC before the said acquisition	1,28,29,889 Equity Shares		
Equity share capital/ total voting capital of the TC after the said acquisition	1,28,29,889 Equity Shares		
Total diluted share/voting capital of the TC after the said acquisition	1,28,29,889 Equity Shares		



Part-B***

Name of the Target Company: *Neuland Laboratories Limited*

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
[REDACTED]	Yes	[REDACTED]

For Davuluri Ownership Trust

Sucheth Rao Davuluri
Trustee



Place: Hyderabad

Date: 25/02/2025

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.